5.75
+0.02(+0.35%)
Currency In USD
| Previous Close | 5.73 |
| Open | 5.74 |
| Day High | 5.75 |
| Day Low | 5.73 |
| 52-Week High | 12.96 |
| 52-Week Low | 3.73 |
| Volume | 48,807 |
| Average Volume | 54,556 |
| Market Cap | 34.66M |
| PE | -0.27 |
| EPS | -21.4 |
| Moving Average 50 Days | 5.6 |
| Moving Average 200 Days | 5.84 |
| Change | 0.02 |
If you invested $1000 in Science 37 Holdings, Inc. (SNCE) since IPO date, it would be worth $28.08 as of October 19, 2025 at a share price of $5.75. Whereas If you bought $1000 worth of Science 37 Holdings, Inc. (SNCE) shares 3 years ago, it would be worth $212.96 as of October 19, 2025 at a share price of $5.75.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data not available
Science 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease Trial
GlobeNewswire Inc.
Oct 08, 2025 12:18 PM GMT
MORRISVILLE, N.C., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, today announced the successful completion of its third FDA inspection, further affirming the quality and compliance of its Dir
Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
GlobeNewswire Inc.
Sep 04, 2025 12:00 PM GMT
MORRISVILLE, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Science 37, the leader in expanding patient access to clinical trials, and Catalent®, a global leader in enabling pharma, biotech, and consumer health partners to optimize product development an
Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial
GlobeNewswire Inc.
Apr 08, 2025 12:00 PM GMT
MORRISVILLE, N.C., April 08, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, today announced the successful completion of its second FDA inspection, reaffirming the quality of its Direct-to-Patient Site